CRNX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -16.29. Updated 2026-07-23.
Crinetics Pharmaceuticals (CRNX) Research Hub
Crinetics Pharmaceuticals (CRNX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-01, shares last closed at 84.95 USD (+0.13%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -16.29, market cap 8.88B. This hub links to the full technical, earnings and options research available for CRNX.
Last updated 2026-09-01 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 84.95 USD (+0.13%) |
| 52-week range | 34.38 USD – 84.95 USD |
| Trend regime | Range |
| 14-day RSI | 77.4 (Overbought) |
| Trailing P/E | -16.29 |
| Market cap | 8.88B |
| Dividend yield | 0.00% |
Available research for CRNX
Covered Call on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRNX: how it works, illustrative setup around the real 84.95 USD price, max profit/loss, breakeven and when to use it. Educational.
CRNX technical analysis: range, last 84.95 USD, RSI 77.4, 52w range 34.38 USD–84.95 USD, real support/resistance. Updated 2026-09-01.
Frequently asked questions
What sector is CRNX in?
Crinetics Pharmaceuticals (CRNX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRNX in an uptrend or downtrend?
As of 2026-09-01, CRNX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRNX's trailing P/E ratio?
CRNX's trailing P/E is -16.29, with a market cap of 8.88B. See the earnings research page for full valuation detail.